Research Topics
| RENIER JOSEPH BRENTJENSSummaryAffiliation: Memorial Sloan-Kettering Cancer Center Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta /CD28 receptorJohn Maher
Department of Human Genetics/Medicine, Gene Transfer and Somatic Cell Engineering Laboratory, and Immunology Program, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
Nat Biotechnol 20:70-5. 2002..These findings have important implications for adoptive immunotherapy of cancer, especially in the context of tumor cells that fail to express major histocompatibility complex antigens and co-stimulatory molecules...
CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemiaRenier J Brentjens
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
Sci Transl Med 5:177ra38. 2013....- Novel cellular therapies for leukemia: CAR-modified T cells targeted to the CD19 antigenRenier J Brentjens
Memorial Sloan Kettering Cancer Center, New York, New York, NY 10065, USA
Hematology Am Soc Hematol Educ Program 2012:143-51. 2012..Recent preclinical studies support additional genetic modifications of CAR-modified T cells to achieve optimal clinical efficacy using this novel adoptive cellular therapy... - Novel approaches to the immunotherapy of B-cell malignancies: An updateRenier J Brentjens
Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Curr Hematol Malig Rep 1:258-63. 2006..Whether findings from these clinical trials, in combination with further preclinical studies, will ultimately translate into improved survival of patients with B-cell malignancies remains to be seen... - Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenograftsRenier J Brentjens
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Clin Cancer Res 13:5426-35. 2007..Here, we investigate the etiologies of treatment failure in this model and design approaches to enhance the efficacy of this adoptive strategy... - Novel approaches to immunotherapy for B-cell malignanciesRenier J Brentjens
Hematology Oncology Division, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
Curr Hematol Rep 4:64-72. 2005..However, whether the promising preclinical and phase I clinical data presented here will ultimately translate into improved survival of patients with B-cell malignancies remains largely unknown... - Novel approaches to immunotherapy for B-cell malignanciesRenier J Brentjens
Hematology Oncology Division, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
Curr Oncol Rep 6:339-47. 2004..However, whether the promising preclinical and phase I clinical data presented here will ultimately translate into improved survival of patients with B-cell malignancies remains largely unknown... - Cellular therapies in acute lymphoblastic leukemiaRenier J Brentjens
Memorial Sloan Kettering Cancer Center, Department of Medicine, Leukemia Service, New York, NY 10065, USA
Curr Opin Mol Ther 11:375-82. 2009..Whether these novel adoptive cell therapies will ultimately result in improved clinical outcomes remains to be determined... 
Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemiasRenier J Brentjens
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Blood 118:4817-28. 2011..These studies are registered at www.clinicaltrials.org as #NCT00466531 (CLL protocol) and #NCT01044069 (B-ALL protocol)...- Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15Renier J Brentjens
Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York, USA
Nat Med 9:279-86. 2003..In addition, transduced T cells from patients with chronic lymphocytic leukemia (CLL) effectively lyse autologous tumor cells. These findings strongly support the clinical feasibility of this therapeutic strategy... - T cell-encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejectionMatthias T Stephan
Center for Cell Engineering, Molecular Pharmacology and Chemistry Program, Memorial Sloan Kettering Cancer Center MSKCC, New York, New York 10021, USA
Nat Med 13:1440-9. 2007..This new strategy of endowing T cells with constitutively expressed costimulatory ligands could be extended to other ligand-receptor pairs and used to enhance any targeted adoptive transfer therapy... - Novel strategies for cancer therapy: the potential of genetically modified T lymphocytesIsabelle Riviere
Department of Medicine, Gene Transfer and Somatic Cell Engineering Laboratory, Immunology Program, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
Curr Hematol Rep 3:290-7. 2004..T cells can also be engineered in an attempt to control their homing, to increase the safety of adoptive T-cell therapies, and express markers that can be tracked by noninvasive imaging technologies... - Successful eradication of established peritoneal ovarian tumors in SCID-Beige mice following adoptive transfer of T cells genetically targeted to the MUC16 antigenAlena A Chekmasova
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
Clin Cancer Res 16:3594-606. 2010.... - Adoptive immunotherapy for B-cell malignancies with autologous chimeric antigen receptor modified tumor targeted T cellsJae H Park
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
Discov Med 9:277-88. 2010.... - Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapyDaniel Hollyman
Gene Transfer and Somatic Cell Engineering Facility, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
J Immunother 32:169-80. 2009..It can also be adapted for other clinical trials involving the expansion and transduction of patient or donor T cells using any CAR or T-cell receptor... - Somatic cell engineering and the immunotherapy of leukemias and lymphomasRenier J Brentjens
Department of Medicine and Clinical Laboratories, Leukemia Service Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
Adv Pharmacol 51:347-70. 2004 - Concurrent visualization of trafficking, expansion, and activation of T lymphocytes and T-cell precursors in vivoIl Kang Na
Department of Immunology, Memorial Sloan Kettering Cancer Center, New York, NY
Blood 116:e18-25. 2010..Because NFAT plays an important role in a wide range of cell types, our system could provide new insights into a variety of biologic processes... - Multifactorial optimization of gammaretroviral gene transfer into human T lymphocytes for clinical applicationAlfonso Quintas Cardama
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Hum Gene Ther 18:1253-60. 2007.... - Adoptive T cell immunotherapy strategies for the treatment of patients with ovarian cancerAlena A Chekmasova
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Discov Med 9:62-70. 2010..To this end, adoptive T cell immunotherapy strategies for the treatment of ovarian carcinomas appear to be particularly promising and are currently being investigated at several centers in both pre-clinical and clinical settings... - Tumor immunotherapy across MHC barriers using allogeneic T-cell precursorsJohannes L Zakrzewski
Department Immunology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, New York 10021, USA
Nat Biotechnol 26:453-61. 2008..We conclude that ex vivo generated MHC-disparate T-cell precursors from any donor can be used universally for 'off-the-shelf' immunotherapy, and can be further enhanced by genetic engineering for targeted immunotherapy... - Sensitive in vivo imaging of T cells using a membrane-bound Gaussia princeps luciferaseElmer B Santos
Department of Radiology, Memorial Sloan Kettering Cancer Center MSKCC, 1275 York Avenue, New York, New York 10021, USA
Nat Med 15:338-44. 2009..This sensitive imaging technology has application to many in vivo cell-based studies in a wide array of mouse models...
Research Grants
- Genetic Targeting of T cells to B cell malignanciesRenier Brentjens; Fiscal Year: 2005..The data derived from these studies will be applied to the rational development of future clinical trials in human subjects with B cell malignancies. ..
- Adoptive Immunotherapy of Cancer with IL-12 Secreting Tumor-Targeted T cellsRENIER JOSEPH BRENTJENS; Fiscal Year: 2010..The goal of this project is to improve the function of these cells to make them better suited to treat patients with persistent cancer after chemotherapy. ..
- Adoptive Immunotherapy of Cancer with IL-12 Secreting Tumor-Targeted T cellsRENIER JOSEPH BRENTJENS; Fiscal Year: 2010..The goal of this project is to improve the function of these cells to make them better suited to treat patients with persistent cancer after chemotherapy. ..